Investors are worried Novo Nordisk's competition with Eli Lilly is heating up and that the first-to-market GLP-1 leader is ...

Doug Long, VP, industry relations, IQVIA, discusses how soaring demand for GLP-1 therapies is driving reimbursement ...

Investors are betting that Lilly will maintain its momentum. Its share price has climbed by a third since the start of 2024; Novo’s has fallen by as much (see chart 2). Lilly’s edge rests on a more ...

As we learn more about GLP-1 drugs like Wegovy and Zepbound, early research suggests that they may be able to improve COPD ...

Ozempic is massively threatening the established diet industry — and it appears that Weight Watchers is now getting the ...

A district court judge in Vermont had earlier ordered that the 30-year-old doctoral student be brought to the state for ...

Catholic cardinals from around the world gathered in the Vatican on Wednesday for the start of the conclave, the centuries-old secret voting ritual to elect a new pope to follow Pope Francis, who died ...

Pharmaceutical company Novo Nordisk (NVO) came out swinging Wednesday morning as the stock initially jumped on its first quarter earnings beat ($0.99 per share vs. estimates of $0.94). Revenue figures ...

GLP-1 receptor agonists remain blockbuster drugs for weight management for people with overweight or obesity. Increasingly, ...

Novo Nordisk has slashed its full-year revenue and profit forecasts for the first time since launching its blockbuster weight ...

WeightWatchers, the 62-year-old program that revolutionized dieting for millions of people around the world, has filed for ...